Amphotericin B

References

• Goodwin RA Jr, Des Prez RM. State of the an: histoplasmosis. Am Rev Respir Dis 1978: 117(5): 929–56
   PubMedGoogle Scholar
• Sarosi GA, Davies SF. Blastomycosis. Am Rev Respir Dis 1979: 120(4): 911–38
   PubMed Web of Science ®Google Scholar
• Drutz DJ, Catanzaro A. Coccidioidomycosis. Am Rev Respir Dis 1978: 117(3): 559–85; 1978: 117(4): 727–71
   PubMed Web of Science ®Google Scholar
• Zeluff BJ. Fungal pneumonia in transplant recipients. Semin Respir Infect (in press)
   Google Scholar
• Johnson PC, Hamill RJ, Sarosi GA. Clinical review: progressive disseminated histoplasmosis in the AIDS patient. Semin Respir Infect 1989: 4(2): 139–46
   PubMedGoogle Scholar
• Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N EnglJ Med 1989: 321 (12): 794–9
   PubMed Web of Science ®Google Scholar
• Gold W, Stout HA, Pagano JF, et al. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. Antibiotics Ann 1955-1956: 579–86
   Google Scholar
• National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med 1985: 103(6 Pt 1): 861–72
   PubMed Web of Science ®Google Scholar
• Medof F G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med 1980: 302(3): 145–55
   PubMed Web of Science ®Google Scholar
• Medoff G. Controversial areas in antifungal chemotherapy: short-course and combination therapy with amphotericin B. Rev Infect Dis 1987: 9(2): 403–7
   PubMedGoogle Scholar
• Utz JP Bennett JE, Brandriss MW, et al. Amphotericin B toxicity. Ann Intern Med 1964: 61: 334–54
   Web of Science ®Google Scholar
• Graybill JR, Craven PC. Antifungal agents used in systemic mycoses: activity and therapeutic use. Drugs 1983: 25(1): 41–62
   PubMed Web of Science ®Google Scholar
• Sarosi GA, Voth DW, Dahl BA, et al. Disseminated histoplasmosis: results of long-term follow-up. Ann Intern Med 1971: 75(4): 511–6
   PubMed Web of Science ®Google Scholar
• Cleary JD, Weisdorf D, Fletcher CV. Effect of infusion rate on amphotericin B-associated febrile reactions. Drug Intell Clin Pharm 1988: 22(10): 769–72
   PubMedGoogle Scholar
• Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother 1985: 27(5): 868–71
   PubMed Web of Science ®Google Scholar
• Burks LC, Aisner J, Fortner CL, et al. Meperidine for the treatment of shaking chills and fever. Arch Intern Med 1980: 140(4): 483–4
   PubMedGoogle Scholar
• Tynes BS, Utz JP, Bennett JE, et al. Reducing amphotericin B reactions: a double-blind study. Am Rev Respir Dis 1963: 87(Feb): 264–8
   PubMedGoogle Scholar
• Graybill JR. Systemic fungal infections: diagnosis and treatment. I. Therapeutic agents. Infect Dis Clin North Am 1988: 2(4): 805–25
   PubMedGoogle Scholar
• Yang DJ, Rankin GO. Nephrotoxicity of antifungal agents. Adverse Drug React Acute Poisoning Rev 1985: 4(1): 37–47
   PubMedGoogle Scholar
• Drutz DJ, Fan JH, Tai TY, et al. Hypokalemic rhabdomyolysis and myoglobinuria following amphotericin B therapy. JAMA 1970: 211(5): 824–6
   PubMed Web of Science ®Google Scholar
• Gertkens JF, Branch RA. The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther 1980: 214(2): 306–11
   PubMed Web of Science ®Google Scholar
• Branch RA. Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 1988: 148(11): 2389–94
   PubMed Web of Science ®Google Scholar
• Chan CS, Tuazon CU, Lessin LS. Amphotericin-B-induced thrombocytopenia. Ann Intern Med 1982: 96(3): 332–3
   PubMed Web of Science ®Google Scholar
• Ellis WG, Sobel RA, Nielsen SI. Leukoencephalopathy in patients treated with amphotericin B methyl ester. J Infect Dis 1982: 146(2): 125–37
   PubMed Web of Science ®Google Scholar
• Barton CH, Pahl M, Vaziri ND, et al. Renal magnesium wasting associated with amphotericin B therapy. AmJ Med 1984: 77(3): 471–4
   PubMed Web of Science ®Google Scholar
• Wright DG, Robichaud KJ, Pizzo PA, et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981: 304(20): 1185–9
   PubMed Web of Science ®Google Scholar
• Dana BW, Dune BG, White RF, et al. Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: absence of significant pulmonary toxicity. Blood 1981: 57(1): 90–4
   PubMed Web of Science ®Google Scholar
• Bindsdiadler DD, Bennett JE. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis 1969: 120(4): 427–36
   PubMed Web of Science ®Google Scholar
• Drutz DJ, Spickard A, Rogers DE, et al. Treatment of disseminated mycotic infections: a new approach to amphotericin B therapy. Am J Med 1968: 45(3): 405–18
   PubMed Web of Science ®Google Scholar
• Chemotherapy of the pulmonary mycoses. Official statement of the American Thoracic Society, adopted by the ATS Board of Directors, November 1987. Am Rev Respir Dis 1988: 138(4): 1078–81
   PubMedGoogle Scholar
• Quinones CA, Reuben AG, Hamill RJ, et al. Chronic cavitary histoplasmosis: failure of oral treatment with ketoconazole. Chest 1989: 95(4): 914–6
   PubMed Web of Science ®Google Scholar
• Parker JD, Sarosi GA, Doto IL, et al. Treatment of chronic pulmonary histoplasmosis. N Engl J Med 1970: 283(30 Jul): 225–9
   PubMed Web of Science ®Google Scholar
• Kravitz GR, Davies SF, Eckman MR, et al. Chronic blastomycotic meningitis. Am J Med 1981: 71(3): 501–5
   PubMed Web of Science ®Google Scholar
• Catanzaro A, Einstein H, Levine B, et al. Ketoconazole for treatment of disseminated coccidioidomycosis. Ann Intern Med 1982: 96(4): 436–40
   PubMed Web of Science ®Google Scholar
• Galgiani JN, Stevens DA, Graybill JR, et al. Ketoconazole therapy of progressive coccidioidomycosis: comparison of400- and 800-mg doses and observations at higher doses. Am J Med 1988: 84(3 Pt 2): 603–10
   PubMed Web of Science ®Google Scholar
• Labadie EL, Hamilton RH. Survival improvement in coccidioidal meningitis by high-dose intrathecal amphotericin B. Arch Intern Med 1986: 146(10): 2013–8
   PubMed Web of Science ®Google Scholar
• Hyde L. Coccidioidal pulmonary cavitation. Dis Chest 1968: 54(Suppl 1): 273–7
   PubMedGoogle Scholar
• Winn WA. A long term study of 300 patients with cavitary-abscess lesions of the lung of coccidioidal origin: an analytical study with special reference to treatment. Dis Chest 1968: 54(Suppl 1): 268
   PubMedGoogle Scholar
• Knoper SR, Galgiani JN. Systemic fungal infections: diagnosis and treatment. I. Coccidioidomycosis. Infect Dis Clin North Am 1988: 2(4): 861–75
   PubMedGoogle Scholar
• Restrepo A, Gomez I, Cano LE, et al. Treatment of paracoccidioidomycosis with ketoconazole: a three-year experience. Am) Med 1983: 74(1B): 48–52
   PubMedGoogle Scholar
• Gerding DN. Treatment of pulmonary sporotrichosis. Semin Respir Infect 1986: 1(1): 61–5
   PubMedGoogle Scholar
• Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981: 94(5): 611–6
   PubMed Web of Science ®Google Scholar
• Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979: 301 (3): 126–31
   PubMed Web of Science ®Google Scholar
• Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987: 317(6): 334–41
   PubMed Web of Science ®Google Scholar
• Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988: 157(4): 624–8
   PubMed Web of Science ®Google Scholar
• Pennington JE. Aspergillus lung disease. Med Clin North Am 1980: 64(3): 475–90
   PubMed Web of Science ®Google Scholar
• Lehrer RI, Howard DH, Sypherd PS, et al. Mucormycosis. Ann Intern Med 1980: 93(Pt 1): 93–108
   PubMed Web of Science ®Google Scholar
• Zuger A, Schuster M. Simberkoff MS, et al. Maintenance amphotericin B for cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988: 109(7): 592–3
   PubMed Web of Science ®Google Scholar
• Sugar AM, Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 1988: 85(4): 481–9
   PubMed Web of Science ®Google Scholar
• Dismukes W, Cloud G, Thompson A, et al. Fluconazole (FLU) versus amphotericin B (AMB) therapy (Rx) of acute cryptococcal meningitis (C.M.). (Abstr) Abstracts of the 1989 ICAAC: 282
   Google Scholar
• McKinsey DS, Gupta MR, Riddler SA, et al. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989: 111(8): 655–9
   PubMed Web of Science ®Google Scholar
• Bronnimann DA, Adam RD, Galgiani JN, et al. Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med 1987: 106(3): 372–9
   PubMed Web of Science ®Google Scholar
• Ampel NM, Fish DG, Dols CL, et al. Coccidioidomycosis (coccy) in HIV-infected subjects: a prospective and retrospective evaluation. (Abstr) Abstracts of the 1989 ICAAC: 163
   Google Scholar